Rubicon Research IPO Final Day: Issue sees 103x subscription driven by strong investor demand; Check other key updates

Rubicon Research IPO: The initial public offering (IPO) of Rubicon Research Limited concluded its final day of public bidding today, October 13. The issue saw an overall subscription of 103.90 times at the end of the session, as per provisional exchange data. The company aims to raise Rs 1377.50 crore from the public offering of 2.84 crore equity shares.

The basis of allotment for the IPO shares is expected to be finalised on October 14, 2025.

Rubicon Research IPO subscription status:

Add Zee Business as a Preferred Source

Overall, investors bid for 170.96 crore shares against the total shares on offer, including major demands from qualified institutional buyers.

Primarily, Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs) booked 130.26 times, 97.61 times, and 35.47 times against their allotted portions, respectively.

In terms of shares, the QIB, NII and RII categories saw subscription of around 116 crore, 43.69 crore and 10.58 crore shares against their reserved portion, respectively.

Rubicon Research IPO details:

The Rubicon Research IPO is a book-building issue of Rs 1,377.50 crore, including a fresh issue of 1.03 crore equity shares of Rs 500 crore and an offer for sale (OFS) of 1.80 crore equity shares of Rs 877.50 crore.

The company has reserved approximately 36,082 equity shares (based on the upper cap) for its eligible employees.

The company plans to utilise the IPO proceeds for debt repayment, funding inorganic growth and for general corporate purposes.

Price band: Rs 461 to Rs 485 per equity share

Face value: Re 1 each

Subscription date: October 9 to October 13, 2025

Lot size: 30 shares

Minimum investment: Rs 14,550 based on the upper end of the price band

Allotment date: October 14, 2025

Listing date: October 16 on BSE and NSE

Rubicon Research company profile:

Rubicon Research Limited is a pharmaceutical formulations company with a strong presence in regulated markets, particularly the United States.

The company has a portfolio of 66 commercialised products and 72 active ANDAs and NDAs approved by the US FDA.

Financially, it reported a net profit of Rs. 43.30 crore on a total income of Rs. 356.95 crore in Q1 FY26, which ended on June 30, 2025, from a net profit of Rs. 25.57 crore on a total income of Rs. 321.90 crore for the previous period.